Phio Pharmaceuticals (PHIO) 10-K 22 Mar 22 2021 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 11, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	001-36304
Entity Registrant Name	PHIO PHARMACEUTICALS CORP.
Entity Central Index Key	0001533040
Entity Tax Identification Number	45-3215903
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	257 Simarano Drive
Entity Address, Address Line Two	Suite 101
Entity Address, City or Town	Marlborough
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01752
City Area Code	508
Local Phone Number	767-3861
Title of 12(b) Security	Common Stock, par value, $0.0001 per share
Trading Symbol	PHIO
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 30,488,446
Entity Common Stock, Shares Outstanding		13,534,996
Auditor Name	BDO USA, LLP
Auditor Location	Boston, Massachusetts
Auditor Firm ID	243

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash	$ 24,057	$ 14,244
Restricted cash	50	50
Prepaid expenses and other current assets	620	870
Total current assets	24,727	15,164
Right of use asset, net	283	400
Property and equipment, net	133	157
Other assets	27	18
Total assets	25,170	15,739
Current liabilities:
Accounts payable	283	728
Accrued expenses	2,660	1,352
Lease liability	125	116
Total current liabilities	3,068	2,196
Lease liability, net of current portion	170	295
Long-term debt	0	231
Total liabilities	3,238	2,722
Commitments and contingencies (Footnote 9)
Stockholders’ equity:
Preferred stock, $0.0001 par value, 10,000,000 shares authorized	0	0
Common stock, $0.0001 par value, 100,000,000 shares authorized; 13,534,996 and 5,780,973 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively	1	1
Additional paid-in capital	138,831	116,629
Accumulated deficit	(116,900)	(103,613)
Total stockholders’ equity	21,932	13,017
Total liabilities and stockholders’ equity	$ 25,170	$ 15,739

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	13,534,996	5,780,973
Common stock, shares outstanding	13,534,996	5,780,973

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating expenses:
Research and development	$ 8,886	$ 3,716
General and administrative	4,625	5,077
Total operating expenses	13,511	8,793
Operating loss	(13,511)	(8,793)
Other income (expense)
Gain on extinguishment of debt	233	0
Interest (expense) income, net	(9)	(1)
Total other income (expense)	224	(1)
Loss before income taxes	(13,287)	(8,794)
Provision for income taxes	0	0
Net loss	$ (13,287)	$ (8,794)
Net loss per share:
Basic and diluted	$ (1.04)	$ (1.92)
Weighted average number of common shares outstanding
Basic and diluted	12,830,809	4,587,346

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 1	$ 100,566	$ (94,819)	$ 5,748
Beginning balance, shares at Dec. 31, 2019	669,433
Cash in lieu of fractional shares for 1:55 reverse stock split		(15)		(15)
Cash in lieu of fractional shares for 1:55 reverse stock split, shares	(1,364)
Issuance of common stock under employee stock purchase plan		1		1
Issuance of common stock under employee stock purchase plan, shares	153
Issuance of common stock and warrants in connection with registered direct and private placement offerings, net of offering costs		4,994		4,994
Issuance of common stock and warrants in connection with registered direct and private placement offerings, net of offering costs, shares	1,910,120
Issuance of common stock, pre-funded warrants and warrants in connection with underwritten public offering, net of offering costs		7,093		7,093
Issuance of common stock, pre-funded warrants and warrants in connection with underwritten public offering, net of offering costs, shares	993,633
Issuance of common stock upon the exercise of warrants		3,856		3,856
Issuance of common stock upon the exercise of warrants, shares	2,205,663
Issuance of common stock upon vesting of restricted stock units		(2)		(2)
Issuance of common stock upon vesting of restricted stock units, shares	3,335
Stock-based compensation expense		136		136
Net loss			(8,794)	(8,794)
Ending balance, value at Dec. 31, 2020	$ 1	116,629	(103,613)	13,017
Ending balance, shares at Dec. 31, 2020	5,780,973
Issuance of common stock, pre-funded warrants and warrants in connection with private placement, net of offering costs		12,669		12,669
Issuance of common stock upon the exercise of warrants		2,146		2,146
Issuance of common stock upon the exercise of warrants, shares	1,083,321
Issuance of common stock upon vesting of restricted stock units		(1)		(1)
Issuance of common stock upon vesting of restricted stock units, shares	3,055
Stock-based compensation expense		480		480
Net loss			(13,287)	(13,287)
Issuance of common stock, pre-funded warrants and warrants in connection with private placement, net of offering costs, shares	4,420,863
Issuance of common stock in registered direct offering, net of offering costs		6,908		6,908
Issuance of common stock in registered direct offering, net of offering costs, shares	2,246,784
Ending balance, value at Dec. 31, 2021	$ 1	$ 138,831	$ (116,900)	$ 21,932
Ending balance, shares at Dec. 31, 2021	13,534,996

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Parenthetical)	12 Months Ended
	Dec. 31, 2020
Statement of Stockholders' Equity [Abstract]
Stockholders' Equity, Reverse Stock Split	1:55 reverse stock split

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (13,287)	$ (8,794)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	75	72
Non-cash lease expense	117	111
Non-cash stock-based compensation	480	136
Forgiveness of debt	(233)	0
Changes in operating assets and liabilities:
Prepaid expenses and other assets	241	(554)
Accounts payable	(445)	(81)
Accrued expenses and other liabilities	1,310	415
Lease liability	(116)	(107)
Net cash used in operating activities	(11,858)	(8,802)
Cash flows from investing activities:
Cash paid for purchase of property and equipment	(51)	(19)
Net cash used in investing activities	(51)	(19)
Cash flows from financing activities:
Net proceeds from the issuance of common stock and warrants	19,577	12,088
Net proceeds from the exercise of warrants	2,146	3,856
Proceeds from debt	0	231
Cash paid in lieu of fractional shares for 1:55 reverse stock split	0	(15)
Payments of taxes for net share settled restricted stock unit issuances	(1)	(2)
Payments of capital lease obligations less than one year	0	(27)
Net cash provided by financing activities	21,722	16,131
Net increase in cash and restricted cash	9,813	7,310
Cash and restricted cash at the beginning of period	14,294	6,984
Cash and restricted cash at the end of period	24,107	14,294
Supplemental disclosure of cash flow information:
Interest paid	$ 8	$ 6

Nature of Operations

Nature of Operations	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations	1. Nature of Operations Phio Pharmaceuticals Corp. (“ Phio we our Company Our operations are being conducted in accordance with guidance provided by the World Health Organization, the Center for Disease Control and governmental authorities, including the implementation of safety measures such as working remotely and flexible scheduling. We expect to continue following these safety measures and may take further actions as we require, as government authorities require or recommend, or as we determine to be in the best interests of our employees. As a result of the coronavirus pandemic, certain of our third-party providers on which we rely have seen impacts to their operations. The Company had and continues to undertake efforts to mitigate potential future impacts by identifying and engaging alternative third-party providers to limit the impact of potential delays on our program’s anticipated timelines. However, the continued impacts to these third-party providers, including, for example, limited availability of certain services and supplies, began significantly affecting our operations in the second quarter of 2021, which resulted in delays to the start of our clinical trials. If measures to overcome the pandemic are insufficient, it could further reduce or delay the availability of supplies and services that we purchase and rely on, which may in turn further slow or delay our preclinical and clinical activities. We believe that the coronavirus pandemic has not had a significant impact on our financial condition to date; however a variety of factors such as those described above, may further impact our operations and slow or diminish our research and development activities, which in turn may impact our financial condition in the future. The extent to which the coronavirus pandemic impacts our results will depend on future developments, which are highly uncertain and cannot be predicted.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“ GAAP 715,000 Principles of Consolidation The consolidated financial statements include the accounts of Phio and its wholly-owned subsidiary, MirImmune, LLC. All material intercompany accounts have been eliminated in consolidation. Uses of Estimates in Preparation of Financial Statements The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The areas subject to significant estimates and judgement include, among others, those related to the fair value of equity awards, accruals for research and development expenses, useful lives of property and equipment, income taxes, and our valuation allowance on our deferred tax assets. On an ongoing basis we evaluate our estimates and base our estimates on historical experience and other relevant assumptions that we believe are reasonable under the circumstances, including as a result of new information that may emerge concerning the coronavirus pandemic. We have made estimates of the impact of the coronavirus pandemic within our financial statements and there may be changes to those estimates in future periods. Actual results could differ materially from these estimates. Restricted Cash Restricted cash consists of certificates of deposit held by financial institutions as collateral for the Company’s corporate credit cards. The following table provides a reconciliation of cash and restricted cash reported within the balance sheet that sum to the total of the same such amounts shown in the statement of cash flows (in thousands): Schedule of Cash December 31, 2021 2020 Cash $ 24,057 $ 14,244 Restricted cash 50 50 Cash and restricted cash shown in the statement of cash flows $ 24,107 $ 14,294 Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company maintains cash balances in several accounts with a financial institution that management believes is creditworthy, which at times are in excess of federally insured limits. These accounts are insured by the Federal Deposit Insurance Corporation (the “ FDIC 250,000 Property and Equipment Property and equipment are stated at cost and depreciated using the straight-line method based on the estimated useful lives of the related assets. The Company provides for depreciation over the assets’ estimated useful lives as follows: Schedule of estimated useful lives Computer equipment 3 years Machinery & equipment 5 years Furniture & fixtures 5 years Leasehold improvements 5 years Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever an event occurs or change in circumstances that the related carrying amounts may not be recoverable. An impairment loss would be recognized based on the difference between the carrying value of the asset and its estimated fair value, which would be determined based on either discounted future cash flows or other appropriate fair value methods. The Company believes no Fair Value of Financial Instruments The carrying amounts reported in the balance sheet for restricted cash, accounts payable and accrued expenses approximate their fair values due to their short-term nature. The Company follows the provisions of the FASB ASC Topic 820, “Fair Value Measurements and Disclosures,” for the Company’s financial assets and liabilities that are re-measured and reported at fair value each reporting period and are re-measured and reported at fair value at least annual using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows: Level 1 – quoted prices in active markets for identical assets or liabilities. Level 2 – other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date. Level 3 – significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date. For the years ended December 31, 2021 and 2020, the Company categorized its restricted cash of $ 50,000 Leases At the inception of a contract, the Company determines whether the contract is or contains a lease based on all relevant facts and circumstances. For contracts that contain a lease, the Company identifies the lease and non-lease components, determines the consideration in the contract and recognizes the classification of the lease as operating or financing. For leases with a term greater than one year, the Company recognizes a liability to make lease payments and an asset representing the right to use the underlying asset during the lease term at the commencement date of the lease. Lease liabilities and the corresponding right of use assets are recorded based on the present value of lease payments to be made over the lease term. The discount rate used to calculate the present value is the rate implicit in the lease, or if not readily determinable, the Company’s incremental borrowing rate. The Company’s incremental borrowing rate is the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right of use asset may be required for items such as initial direct costs or incentives received. Lease payments on operating leases, including scheduled increases, are recognized on a straight-line basis over the expected term of the lease. Lease payments on financing leases are recognized using the effective interest method. Debt On March 27, 2020, the United States enacted the Coronavirus Aid, Relief, and Economic Security Act (the “ CARES Act PPP The Company followed the guidance under the Financial Accounting Standards Board (the “ FASB ASC Debt ASC 470 Derivative Financial Instruments Financial instruments that meet the definition of a derivative are classified as an asset or liability and measured at fair value on the issuance date and are revalued on each subsequent balance sheet date. The changes in fair value are recognized as current period income or loss. Financial instruments that do not meet the definition of a derivative are classified as equity and measured at fair value and recorded as additional paid-in capital in stockholders’ equity at the date of issuance. No further adjustments to their valuation are made. Research and Development Expenses Research and development expenses relate to compensation and benefits for research and development personnel, facility-related expenses, supplies, external services, costs to acquire technology licenses, research activities under our research collaborations, expenses associated with preclinical and clinical development activities and other operating costs. Research and development expenses are charged to expense as incurred. Payments made by the Company in advance for research and development services not yet provided and/or for materials not yet received are recorded as prepaid expenses and expensed when the service has been performed or when the goods have been received. Accrued liabilities are recorded related to those expenses for which vendors have not yet billed the Company with respect to services provided and/or materials that it has received. Accrued liabilities for the services provided by contract research organizations are recorded during the period incurred based on such estimates and assumptions as expected cost, passage of time, the achievement of milestones and other information available to us and are assessed on a quarterly basis. Actual results may differ from these estimates and could have a material impact on the Company’s reported results. The Company’s historical accrual estimates have not been materially different from its actual costs. Collaborative Arrangements The Company follows the provisions of the FASB ASC Topic 808, “Collaborative Arrangements,” (“ Topic 808 Topic 606 Payments or reimbursements that are the result of a collaborative relationship instead of a customer relationship, such as co-development activities, are recorded as increases or decreases to research and development expense. Patents and Patent Application Costs Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as general and administrative costs as incurred. Stock-based Compensation The Company follows the provisions of the FASB ASC Topic 718, “ Compensation — Stock Compensation ASC 718 Stock-based compensation expense recognized in the financial statements is based on awards that are ultimately expected to vest. Accordingly, we are also required to estimate forfeitures at the time of grant and to revise those estimates in subsequent periods if actual forfeitures differ from estimates. We use historical data to estimate pre-vesting award forfeitures and record stock-based compensation expense only for those awards that are expected to vest. Our forfeiture rate estimates are based on an analysis of our actual forfeiture experience, employee turnover behavior, and other factors. The impact of any adjustments to our forfeiture rates is recorded as a cumulative adjustment in the period of adjustment. To the extent that actual forfeitures differ from our estimates, the difference is recorded as a cumulative adjustment in the period the estimates are revised. Income Taxes The Company recognizes assets or liabilities for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with the FASB ASC Topic 740, “Accounting for Income Taxes” ASC 740 . Immaterial Revision In 2021, the Company completed an Internal Revenue Code Section 382 analysis of its historical net operating loss carry-forward amount. As a result, the prior year net operating loss carry-forward was determined to be limited. See Note 13 Income Taxes Comprehensive Loss The Company’s comprehensive loss is equal to its net loss for all periods presented. Net Loss per Share Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted net loss per share is computed by dividing the Company’s net loss by the weighted average number of common shares outstanding and the impact of all dilutive potential common shares outstanding, except where such dilutive potential common shares would be anti-dilutive. Dilutive potential common shares primarily consist of warrants, restricted stock units and stock options.

Liquidity and Going Concern

Liquidity and Going Concern	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Going Concern	3. Liquidity and Going Concern The Company has reported recurring losses from operations since its inception and expects to continue to have negative cash flows from operations for the foreseeable future. Historically, the Company’s primary source of funding has been from sales of its securities. The Company’s ability to continue to fund its operations is dependent on obtaining funding from third parties, such as proceeds from the issuance of debt, sale of equity, or strategic opportunities, in order to maintain its operations. This is dependent on a number of factors, including the market demand or liquidity of the Company’s common stock. There is no guarantee that debt, additional equity or other funding will be available to us on acceptable terms, or at all. If we fail to obtain additional funding when needed, we would be forced to scale back or terminate our operations or seek to merge with or to be acquired by another company. While we believe that the coronavirus pandemic has not had a significant impact on our financial condition and results of operations at this time, the potential economic impact brought by, and the duration of, the coronavirus pandemic is difficult to assess or predict. There may be developments outside of our control that require us to adjust our operating plans and given the nature of the situation, we cannot reasonably estimate the impact of the coronavirus pandemic on our financial conditions, results of operations or cash flows in the future. The Company believes that its existing cash should be sufficient to fund operations for at least the next 12 months from the date of the release of these financial statements.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	12 Months Ended
	Dec. 31, 2021
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements	4. Recent Accounting Pronouncements In December 2019, the FASB issued Accounting Standards Update (“ ASU Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ASU 2019-12 In August 2020, the FASB issued ASU 2020-06, “ Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40)” ASU 2020-06 In May 2021, the FASB issued ASU 2021-04, “ Earnings per Share (Topic 260), Debt – Modifications and Extinguishments (Subtopic 470-50), Compensation – Stock Compensation (Topic 718), and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40) ASU 2021-04

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Property and Equipment	5. Property and Equipment The following table summarizes the Company’s major classes of property and equipment: Schedule of property and equipment December 31, 2021 2020 Computer equipment $ 108 $ 195 Machinery & equipment 1,035 992 Furniture & fixtures 49 46 Leasehold improvements 46 46 Total gross fixed assets 1,238 1,279 Less: accumulated depreciation and amortization (1,105 ) (1,122 ) Property and equipment, net $ 133 $ 157 Depreciation and amortization expense for the years ended December 31, 2021 and 2020 was $ 75,000 72,000

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued Expenses	6. Accrued Expenses Accrued expenses consist of the following, in thousands: Schedule of accrued expenses and other current liabilities December 31, 2021 2020 Compensation and benefits $ 572 $ 618 Professional fees 102 81 Research and development costs 1,986 549 Other – 104 Total accrued expenses and other current liabilities $ 2,660 $ 1,352

Leases

Leases	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Leases	7. Leases In January 2019, the Company amended the lease for its corporate headquarters and primary research facility in Marlborough, Massachusetts. The lease is for a total of 7,581 March 31, 2024 The lease for our corporate headquarters represents substantially all of our significant lease obligations. The amounts reported in the consolidated balance sheets for operating leases in which the Company is the lessee and other supplemental balance sheet information is set forth as follows, in thousands, except the lease term (number of years) and discount rate: Schedule of lease amounts recorded in balance sheet December 31, 2021 December 31, 2020 Assets Right of use asset $ 283 $ 400 Liabilities Lease liability, current 125 116 Lease liability, non-current 170 295 Total lease liability $ 295 $ 411 Lease Term and Discount Rate Weighted average remaining lease term 2.25 3.25 Weighted average discount rate 4.70 4.70 Operating lease costs included in operating expense were $ 132,000 132,000 Cash paid for the amounts included in the measurement of the operating lease liability on the Company’s consolidated balance sheets and included within changes in the lease liability in the operating activities of our consolidated statement of cash flows was $ 131,600 127,800 Future lease payments for our non-cancellable operating leases and a reconciliation to the carrying amount of the operating lease liability presented in the consolidated balance sheet as of December 31, 2021 is as follows, in thousands: Aggregate future minimum lease payments 2022 $ 135 2023 140 2024 35 Total lease payments 310 Less: Imputed interest (15 ) Total operating lease liabilities (includes current portion) $ 295

Debt

Debt	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Debt	8. Debt In May 2020, the Company received loan proceeds in the amount of $ 231,252 May 11, 2022 1 SBA The Company followed the guidance under ASC 470 in assessing the accounting for the PPP loan proceeds. Per ASC 470, the Company recorded a liability on the balance sheet for the full amount of PPP loan proceeds received and accrued interest over the term of the loan. The Company believed it used the loan proceeds for eligible purposes and applied for full loan forgiveness. In February 2021, the SBA approved the Company’s application for full loan forgiveness, and the full amount of the PPP loan was remitted to the lender for forgiveness. Upon loan forgiveness, the Company recognized a gain on the extinguishment of debt of $ 233

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. Commitments and Contingencies License Commitments The Company acquires assets under development and enters into research and development arrangements with third parties that often require milestone and royalty payments based on the progress of the asset through development stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency. In certain agreements, the Company is required to make royalty payments based upon a percentage of the sales of the products licensed pursuant to such agreements. Because of the contingent nature of these payments, they are not included in the table of contractual obligations shown below. During the years ended December 31, 2021 and 2020, the Company did not trigger any milestone payments. The Company’s contractual license obligations that will require future cash payments as of December 31, 2021 are as follows, in thousands: Schedule of future cash payments for contractual license obligations Year Ending December 31, 2022 $ 100 2023 100 2024 100 2025 100 2026 100 Thereafter 300 Total $ 800 The Company applies the disclosure provisions of the FASB ASC Topic 460, “ Guarantor’s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others ASC 460 Litigation From time to time, the Company is party to legal proceedings. There are none deemed to be material at this time. Accordingly, the Company has not accrued any liabilities in its consolidated financial statements related to proceedings.

Stockholders_ Equity

Stockholders’ Equity	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Stockholders’ Equity	10. Stockholders’ Equity January 2021 Private Placement — 4,420,863 3.07 140,065 January 2021 Pre-Funded Warrants 3.069 3,420,696 3.00 January 2021 Warrants Private Placement HCW 342,070 3.8375 January 2021 Placement Agent Warrants 12,669,000 February 2021 Registered Direct Offering — 2,246,784 3.42 Offering 168,509 4.275 February 2021 Placement Agent Warrants 6,908,000 February 2020 Registered Direct Offering and Private Placement — February 2020 Registered Offering 197,056 8.705 197,056 0.125 8.71 February 2020 Registered Direct Warrants 14,779 11.0375 February 2020 Placement Agent Warrants 1,467,000 February 2020 Underwritten Public Offering 993,633 4.00 2020 Pre-Funded Warrants 1,006,367 3.999 February 2020 Warrants 2,000,000 4.00 February 2020 Underwritten Offering 0.001 150,000 5.00 February 2020 Underwriter Warrants In connection with the February 2020 Underwritten Offering, the Company also granted to the underwriter, HCW, a 30-day option to purchase up to an additional 300,000 3.999 300,000 0.001 300,000 Net proceeds from the February 2020 Underwritten Offering were $ 7,093,000 April 2020 Registered Direct Offering and Private Placement April 2020 Offering 1,713,064 2.21 1,713,064 0.125 2.21 April 2020 Warrants 128,480 2.9188 April 2020 Placement Agent Warrants 3,527,000 Warrants The Company first assesses the warrants it issues under the FASB ASC Topic 480, “ Distinguishing Liabilities from Equity ASC 480 The Company then applies and follows the applicable accounting guidance in ASC 815. Financial instruments are accounted for as either derivative liabilities or as equity instruments depending on the specific terms of the agreement. The warrants issued in the Private Placement and the Offering do not meet the definition of a derivative instrument as they are indexed to the Company’s common stock and classified within stockholders’ equity, as are the warrants issued in the Company’s prior financing transactions. Based on this determination, the Company’s warrants are classified within stockholders’ equity. The following table summarizes the Company’s outstanding equity-classified warrants at December 31, 2021: Summary of outstanding warrants Exercise Expiration Balance December 31, Warrants Warrants Warrants Balance December 30, Description Price Date 2020 Issued Exercised Expired 2021 December 2016 Warrants $ 495.00 12/21/2021 23,233 – – (23,233 ) – April 2018 Warrants $ 173.25 5/31/2023 20,599 – – – 20,599 April 2018 Placement Agent Warrants $ 223.00 4/9/2023 1,373 – – – 1,373 October 2018 Warrants $ 10.45 10/3/2025 389,610 – – – 389,610 October 2018 Underwriter Warrants $ 13.06 10/1/2023 29,220 – – – 29,220 November 2019 Placement Agent Warrants $ 6.875 11/18/2024 13,636 – – – 13,636 February 2020 Registered Direct Warrants $ 8.71 8/6/2025 197,056 – – – 197,056 February 2020 Placement Agent Warrants $ 11.0375 2/4/2025 14,779 – – – 14,779 February 2020 Warrants $ 4.00 2/13/2025 1,326,500 – – – 1,326,500 February 2020 Underwriter Warrants $ 5.00 2/11/2025 150,000 – – – 150,000 April 2020 Warrants $ 2.21 10/2/2025 1,284,798 – (856,532 ) – 428,266 April 2020 Placement Agent Warrants $ 2.9188 3/31/2025 128,480 – (86,724 ) – 41,756 January 2021 Pre-Funded Warrants $ 0.001 No expiration – 140,065 (140,065 ) – – January 2021 Warrants $ 3.00 7/27/2026 – 3,420,696 – – 3,420,696 January 2021 Placement Agent Warrants $ 3.8375 7/27/2026 – 342,070 – – 342,070 February 2021 Placement Agent Warrants $ 4.275 2/12/2026 – 168,509 – – 168,509 3,579,284 4,071,340 (1,083,321 ) (23,233 ) 6,544,070 The Company received net proceeds of $ 2,146,000 3,856,000 Of the warrants exercised during the year ended December 31, 2020, 428,266 225,796 no

Net Loss per Share

Net Loss per Share	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Net Loss per Share	11. Net Loss per Share The following table sets forth the potential common shares excluded from the calculation of net loss per share because their inclusion would be anti-dilutive: Schedule of antidilutive stock December 31, 2021 2020 Options to purchase common stock 2,499 2,570 Unvested restricted stock units 367,101 9,699 Warrants to purchase common stock 6,544,070 3,579,284 Total 6,913,670 3,591,553

Stock-based Compensation

Stock-based Compensation	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Stock-based Compensation	12. Stock-based Compensation Stock Plans The Company’s approved equity plans include the Phio Pharmaceuticals Corp. 2020 Long Term Incentive Plan (the “ 2020 Plan 2012 Plan As of December 31, 2021, there were an aggregate of 1,267,675 2,499 367,101 RSUs 894,227 Restricted Stock Units RSUs are issued under the 2020 Plan or as inducement grants issued outside of the plan to new employees. RSUs are generally subject to graded vesting and the satisfaction of service requirements. Upon vesting, each outstanding RSU will be exchanged for one share of the Company’s common stock. Employee RSU recipients may elect to net share settle upon vesting, in which case the Company pays the employee’s income taxes due upon vesting and withholds a number of shares of equal value. The fair value of the RSUs awarded are based upon the Company’s closing stock price at the grant date and are expensed over the requisite service period. The following table summarizes the activity of the Company’s RSUs for the year ended December 31, 2021: Summary of RSU activity Number Weighted- Unvested units at December 31, 2020 9,699 $ 19.97 Granted 360,750 2.94 Vested (3,348 ) 22.67 Forfeited – – Unvested units at December 31, 2021 367,101 $ 3.21 Stock-based compensation expense related to RSUs was $ 443,000 85,000 The aggregate fair value of awards that vested during the year ended December 31, 2021 was $ 9,400 As of December 31, 2021, the compensation expense for all unvested RSUs in the amount of approximately $ 770,000 2.03 Stock Options Stock options are issued under the 2020 Plan or as inducement grants issued outside of the plan to new employees. Stock options are generally subject to graded vesting and the satisfaction of service requirements. Upon the exercise of a stock option, the Company issues new shares and delivers them to the recipient. The Company does not expect to repurchase shares to satisfy stock option exercises. The Company uses the Black-Scholes option-pricing model to determine the fair value of all its option grants. The risk-free interest rate used for each grant was based upon the yield on zero-coupon U.S. Treasury securities with a term similar to the expected life of the related option. The Company’s expected stock price volatility assumption is based upon the Company’s own implied volatility. As the Company has limited stock option exercise information, the expected life assumption used for option grants is based upon the simplified method provided for under ASC 718. The dividend yield assumption is based upon the fact that the Company has never paid cash dividends and presently has no intention of paying cash dividends. The Company did not grant stock options during the years ended December 31, 2021 and December 31, 2020. The following table summarizes the activity of the Company’s stock option plan for the year ended December 31, 2021: Summary of Stock Option Activity Total Number Weighted- Weighted- Aggregate Balance at December 31, 2020 2,570 $ 3,334.06 Granted – – Exercised – – Cancelled (71 ) 946.27 Balance at December 31, 2021 2,499 $ 3,401.90 5.39 $ – Exercisable at December 31, 2021 2,153 $ 3,932.78 5.20 $ – Stock-based compensation expense related to stock options for the years ended December 31, 2021 and 2020 was $ 37,000 51,000 As of December 31, 2021, the compensation expense for all unvested stock options in the amount of approximately $ 21,000 0.58 There is no income tax benefit as the Company is currently operating at a loss and an actual income tax benefit may not be realized. Compensation Expense Related to Equity Awards The following table sets forth total stock-based compensation expense for the years ended December 31, 2021 and 2020, in thousands: Details of Stock-based Compensation Expense December 31, 2021 2020 Research and development $ 117 $ 22 General and administrative 363 114 Total stock-based compensation $ 480 $ 136

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	13. Income Taxes The provisions for income taxes for the years ended December 31, 2021 and 2020 are as follows, in thousands: Components of Federal and State Income Tax Expense Years Ended December 31, 2021 2020 Current Federal $ – $ – State – – Total current – – Deferred Federal (3,016 ) 9,780 State (1,329 ) 5,548 Total deferred (4,345 ) 15,328 Valuation allowance 4,345 (15,328 ) Total provision for income taxes $ – $ – Reconciliation of the effective income tax rate to the U.S. statutory rate is as follows: Schedule of effective income tax reconciliation Years Ended December 31, 2021 2020 Federal statutory rate 21.0 21.0 State income taxes, net of federal benefit 8.5 6.7 Non-deductible expenses   0.2   (0.5 )  Income tax credits 4.3 2.1 Valuation allowance ( 34.0 ) ( 29.3 ) Effective tax rate 0.0 0.0 The Company recognizes deferred tax assets and liabilities to reflect the tax effects of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with ASC 740. These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. ASC 740 requires that a valuation allowance be established when management determines that it is more likely than not that all or a portion of a deferred asset will not be realized. The Company evaluates the realizability of its net deferred income tax assets and valuation allowances as necessary, at least on an annual basis. During this evaluation, the Company reviews its forecasts of income in conjunction with other positive and negative evidence surrounding the realizability of its deferred income tax assets to determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the Company’s income tax provision or benefit. The components of the Company’s deferred tax assets are as follows, in thousands: Schedule of deferred tax assets Years Ending December 31, 2021 2020 Deferred tax assets: Net operating loss carryforwards $ 10,150 $ 6,355 Tax credit carryforwards 946 – Stock-based compensation 1,363 1,374 Licensing deduction deferral 2,018 2,376 Lease liability 79 111 Other timing differences 169 196 Deferred tax assets 14,725 10,412 Deferred tax liabilities: Right of use asset (76 ) (108 ) Deferred tax liability (76 ) (108 ) Valuation allowance (14,649 ) (10,304 ) Net deferred tax asset $ – $ – The Company evaluated the realizability of its net deferred tax assets and concluded that, in accordance with the applicable accounting standards, that it is more likely than not that the Company may not realize the benefit of all of its deferred tax assets. Accordingly, a valuation allowance against 100% of its deferred tax assets has been recorded. Significant judgment is required in the evaluation of deferred tax benefits and differences in future results from our estimates could result in material differences in the realization of these assets. As of December 31, 2021, the Company had federal net operating loss carryforwards of approximately $ 42,900,000 18,100,000 42,579,000 321,000 2031 2038 573,000 472,000 2042 Ownership changes may limit the amount of net operating loss carryforwards or research and development tax credit carryforwards that can be utilized to offset future taxable income or tax liability. In general, an ownership change, as defined by Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the “ Code During 2021, the Company completed an assessment of the available net operating loss and tax credit carryforwards under Section 382 and 383 and determined that the Company underwent six ownership changes during the period from 2012 to 2021. As a result, net operating loss and tax credit carryforwards attributable to the pre-ownership changes are subject to substantial annual limitations under Section 382 and 383 of Code due to the ownership changes. The Company has adjusted its net operating loss and tax credit carryforwards to address the impact of the ownership changes. This resulted in a reduction of available federal and state net operating loss carryforwards of approximately $ 55,000,000 70,000,000 1,400,000 700,000 15,952,000 2,017,000 17,969,000 The recognition and measurement of benefits related to the Company’s tax positions requires significant judgment, as uncertainties often exist with respect to new laws, new interpretations of existing laws, and rulings by taxing authorities. The Company follows a more-likely-than not threshold for financial statement recognition and measurement of a tax position taken, or expected to be taken in a tax return. The guidance relates to, amongst other things, classification, accounting for interest and penalties associated with tax positions, and disclosure requirements. Any interest and penalties accrued related to uncertain tax positions are recorded as tax expense. Differences between actual results and the Company’s assumptions or changes in the Company’s assumptions in future periods are recorded in the period they become known. The Company has not recorded any uncertain tax positions as of December 31, 2021 or 2020. The Company does not believe there will be any material changes in its unrecognized tax positions over the next 12 months. The Company has not incurred any interest or penalties. In the event that the Company is assessed interest or penalties at some point in the future, they will be classified in the financial statements as general and administrative expenses. The Company files income tax returns in the United States, Massachusetts and New Jersey. The Company is subject to tax examinations for federal and state purposes for tax years 2013 through 2021.

Collaboration and License Agree

Collaboration and License Agreements	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaboration and License Agreements	14. Collaboration and License Agreements In March 2021, the Company entered into a clinical development collaboration with AgonOx, Inc. (“ AgonOx DP TIL As part of its business, the Company enters into licensing agreements with third parties that often require milestone and royalty payments based on the progress of the asset through development stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency. In certain agreements, the Company is required to make royalty payments based upon a percentage of the sales of the products licensed pursuant to such agreements. The expenditures required under these arrangements may be material individually in the event that the Company develops product candidates covered by the intellectual property licensed under any such arrangement, and in the unlikely event that milestones for multiple products covered by these arrangements were reached in the same period, the aggregate charge to expense could be material to the results of operations. In addition, these arrangements often give the Company discretion to unilaterally terminate development of the product, which would allow the Company to avoid making the contingent payments; however, the Company is unlikely to cease development if the compound successfully achieves clinical testing objectives. Advirna LLC. Advirna Our rights under the Advirna agreement will expire upon the later of: (i) the expiration of the last-to-expire of the “patent rights” (as defined therein) included in the Advirna agreement; or (ii) the abandonment of the last-to-be abandoned of such patents, unless earlier terminated in accordance with the provisions of the agreement.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“ GAAP 715,000
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Phio and its wholly-owned subsidiary, MirImmune, LLC. All material intercompany accounts have been eliminated in consolidation.
Uses of Estimates in Preparation of Financial Statements	Uses of Estimates in Preparation of Financial Statements The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The areas subject to significant estimates and judgement include, among others, those related to the fair value of equity awards, accruals for research and development expenses, useful lives of property and equipment, income taxes, and our valuation allowance on our deferred tax assets. On an ongoing basis we evaluate our estimates and base our estimates on historical experience and other relevant assumptions that we believe are reasonable under the circumstances, including as a result of new information that may emerge concerning the coronavirus pandemic. We have made estimates of the impact of the coronavirus pandemic within our financial statements and there may be changes to those estimates in future periods. Actual results could differ materially from these estimates.
Restricted Cash	Restricted Cash Restricted cash consists of certificates of deposit held by financial institutions as collateral for the Company’s corporate credit cards. The following table provides a reconciliation of cash and restricted cash reported within the balance sheet that sum to the total of the same such amounts shown in the statement of cash flows (in thousands): Schedule of Cash December 31, 2021 2020 Cash $ 24,057 $ 14,244 Restricted cash 50 50 Cash and restricted cash shown in the statement of cash flows $ 24,107 $ 14,294
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company maintains cash balances in several accounts with a financial institution that management believes is creditworthy, which at times are in excess of federally insured limits. These accounts are insured by the Federal Deposit Insurance Corporation (the “ FDIC 250,000
Property and Equipment	Property and Equipment Property and equipment are stated at cost and depreciated using the straight-line method based on the estimated useful lives of the related assets. The Company provides for depreciation over the assets’ estimated useful lives as follows: Schedule of estimated useful lives Computer equipment 3 years Machinery & equipment 5 years Furniture & fixtures 5 years Leasehold improvements 5 years
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever an event occurs or change in circumstances that the related carrying amounts may not be recoverable. An impairment loss would be recognized based on the difference between the carrying value of the asset and its estimated fair value, which would be determined based on either discounted future cash flows or other appropriate fair value methods. The Company believes no
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying amounts reported in the balance sheet for restricted cash, accounts payable and accrued expenses approximate their fair values due to their short-term nature. The Company follows the provisions of the FASB ASC Topic 820, “Fair Value Measurements and Disclosures,” for the Company’s financial assets and liabilities that are re-measured and reported at fair value each reporting period and are re-measured and reported at fair value at least annual using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows: Level 1 – quoted prices in active markets for identical assets or liabilities. Level 2 – other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date. Level 3 – significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date. For the years ended December 31, 2021 and 2020, the Company categorized its restricted cash of $ 50,000
Leases	Leases At the inception of a contract, the Company determines whether the contract is or contains a lease based on all relevant facts and circumstances. For contracts that contain a lease, the Company identifies the lease and non-lease components, determines the consideration in the contract and recognizes the classification of the lease as operating or financing. For leases with a term greater than one year, the Company recognizes a liability to make lease payments and an asset representing the right to use the underlying asset during the lease term at the commencement date of the lease. Lease liabilities and the corresponding right of use assets are recorded based on the present value of lease payments to be made over the lease term. The discount rate used to calculate the present value is the rate implicit in the lease, or if not readily determinable, the Company’s incremental borrowing rate. The Company’s incremental borrowing rate is the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right of use asset may be required for items such as initial direct costs or incentives received. Lease payments on operating leases, including scheduled increases, are recognized on a straight-line basis over the expected term of the lease. Lease payments on financing leases are recognized using the effective interest method.
Debt	Debt On March 27, 2020, the United States enacted the Coronavirus Aid, Relief, and Economic Security Act (the “ CARES Act PPP The Company followed the guidance under the Financial Accounting Standards Board (the “ FASB ASC Debt ASC 470
Derivative Financial Instruments	Derivative Financial Instruments Financial instruments that meet the definition of a derivative are classified as an asset or liability and measured at fair value on the issuance date and are revalued on each subsequent balance sheet date. The changes in fair value are recognized as current period income or loss. Financial instruments that do not meet the definition of a derivative are classified as equity and measured at fair value and recorded as additional paid-in capital in stockholders’ equity at the date of issuance. No further adjustments to their valuation are made.
Research and Development Expenses	Research and Development Expenses Research and development expenses relate to compensation and benefits for research and development personnel, facility-related expenses, supplies, external services, costs to acquire technology licenses, research activities under our research collaborations, expenses associated with preclinical and clinical development activities and other operating costs. Research and development expenses are charged to expense as incurred. Payments made by the Company in advance for research and development services not yet provided and/or for materials not yet received are recorded as prepaid expenses and expensed when the service has been performed or when the goods have been received. Accrued liabilities are recorded related to those expenses for which vendors have not yet billed the Company with respect to services provided and/or materials that it has received. Accrued liabilities for the services provided by contract research organizations are recorded during the period incurred based on such estimates and assumptions as expected cost, passage of time, the achievement of milestones and other information available to us and are assessed on a quarterly basis. Actual results may differ from these estimates and could have a material impact on the Company’s reported results. The Company’s historical accrual estimates have not been materially different from its actual costs.
Collaborative Arrangements	Collaborative Arrangements The Company follows the provisions of the FASB ASC Topic 808, “Collaborative Arrangements,” (“ Topic 808 Topic 606 Payments or reimbursements that are the result of a collaborative relationship instead of a customer relationship, such as co-development activities, are recorded as increases or decreases to research and development expense.
Patents and Patent Application Costs	Patents and Patent Application Costs Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as general and administrative costs as incurred.
Stock-based Compensation	Stock-based Compensation The Company follows the provisions of the FASB ASC Topic 718, “ Compensation — Stock Compensation ASC 718 Stock-based compensation expense recognized in the financial statements is based on awards that are ultimately expected to vest. Accordingly, we are also required to estimate forfeitures at the time of grant and to revise those estimates in subsequent periods if actual forfeitures differ from estimates. We use historical data to estimate pre-vesting award forfeitures and record stock-based compensation expense only for those awards that are expected to vest. Our forfeiture rate estimates are based on an analysis of our actual forfeiture experience, employee turnover behavior, and other factors. The impact of any adjustments to our forfeiture rates is recorded as a cumulative adjustment in the period of adjustment. To the extent that actual forfeitures differ from our estimates, the difference is recorded as a cumulative adjustment in the period the estimates are revised.
Income Taxes	Income Taxes The Company recognizes assets or liabilities for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with the FASB ASC Topic 740, “Accounting for Income Taxes” ASC 740 .
Immaterial Revision	Immaterial Revision In 2021, the Company completed an Internal Revenue Code Section 382 analysis of its historical net operating loss carry-forward amount. As a result, the prior year net operating loss carry-forward was determined to be limited. See Note 13 Income Taxes
Comprehensive Loss	Comprehensive Loss The Company’s comprehensive loss is equal to its net loss for all periods presented.
Net Loss per Share	Net Loss per Share Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted net loss per share is computed by dividing the Company’s net loss by the weighted average number of common shares outstanding and the impact of all dilutive potential common shares outstanding, except where such dilutive potential common shares would be anti-dilutive. Dilutive potential common shares primarily consist of warrants, restricted stock units and stock options.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of Cash	Restricted cash consists of certificates of deposit held by financial institutions as collateral for the Company’s corporate credit cards. The following table provides a reconciliation of cash and restricted cash reported within the balance sheet that sum to the total of the same such amounts shown in the statement of cash flows (in thousands): Schedule of Cash December 31, 2021 2020 Cash $ 24,057 $ 14,244 Restricted cash 50 50 Cash and restricted cash shown in the statement of cash flows $ 24,107 $ 14,294
Schedule of estimated useful lives	Schedule of estimated useful lives Computer equipment 3 years Machinery & equipment 5 years Furniture & fixtures 5 years Leasehold improvements 5 years

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	Schedule of property and equipment December 31, 2021 2020 Computer equipment $ 108 $ 195 Machinery & equipment 1,035 992 Furniture & fixtures 49 46 Leasehold improvements 46 46 Total gross fixed assets 1,238 1,279 Less: accumulated depreciation and amortization (1,105 ) (1,122 ) Property and equipment, net $ 133 $ 157

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2021
Payables and Accruals [Abstract]
Schedule of accrued expenses and other current liabilities	Schedule of accrued expenses and other current liabilities December 31, 2021 2020 Compensation and benefits $ 572 $ 618 Professional fees 102 81 Research and development costs 1,986 549 Other – 104 Total accrued expenses and other current liabilities $ 2,660 $ 1,352

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Schedule of lease amounts recorded in balance sheet	Schedule of lease amounts recorded in balance sheet December 31, 2021 December 31, 2020 Assets Right of use asset $ 283 $ 400 Liabilities Lease liability, current 125 116 Lease liability, non-current 170 295 Total lease liability $ 295 $ 411 Lease Term and Discount Rate Weighted average remaining lease term 2.25 3.25 Weighted average discount rate 4.70 4.70
Aggregate future minimum lease payments	Aggregate future minimum lease payments 2022 $ 135 2023 140 2024 35 Total lease payments 310 Less: Imputed interest (15 ) Total operating lease liabilities (includes current portion) $ 295

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Schedule of future cash payments for contractual license obligations	Schedule of future cash payments for contractual license obligations Year Ending December 31, 2022 $ 100 2023 100 2024 100 2025 100 2026 100 Thereafter 300 Total $ 800

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Summary of outstanding warrants	Summary of outstanding warrants Exercise Expiration Balance December 31, Warrants Warrants Warrants Balance December 30, Description Price Date 2020 Issued Exercised Expired 2021 December 2016 Warrants $ 495.00 12/21/2021 23,233 – – (23,233 ) – April 2018 Warrants $ 173.25 5/31/2023 20,599 – – – 20,599 April 2018 Placement Agent Warrants $ 223.00 4/9/2023 1,373 – – – 1,373 October 2018 Warrants $ 10.45 10/3/2025 389,610 – – – 389,610 October 2018 Underwriter Warrants $ 13.06 10/1/2023 29,220 – – – 29,220 November 2019 Placement Agent Warrants $ 6.875 11/18/2024 13,636 – – – 13,636 February 2020 Registered Direct Warrants $ 8.71 8/6/2025 197,056 – – – 197,056 February 2020 Placement Agent Warrants $ 11.0375 2/4/2025 14,779 – – – 14,779 February 2020 Warrants $ 4.00 2/13/2025 1,326,500 – – – 1,326,500 February 2020 Underwriter Warrants $ 5.00 2/11/2025 150,000 – – – 150,000 April 2020 Warrants $ 2.21 10/2/2025 1,284,798 – (856,532 ) – 428,266 April 2020 Placement Agent Warrants $ 2.9188 3/31/2025 128,480 – (86,724 ) – 41,756 January 2021 Pre-Funded Warrants $ 0.001 No expiration – 140,065 (140,065 ) – – January 2021 Warrants $ 3.00 7/27/2026 – 3,420,696 – – 3,420,696 January 2021 Placement Agent Warrants $ 3.8375 7/27/2026 – 342,070 – – 342,070 February 2021 Placement Agent Warrants $ 4.275 2/12/2026 – 168,509 – – 168,509 3,579,284 4,071,340 (1,083,321 ) (23,233 ) 6,544,070

Net Loss per Share (Tables)

Net Loss per Share (Tables)	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Schedule of antidilutive stock	Schedule of antidilutive stock December 31, 2021 2020 Options to purchase common stock 2,499 2,570 Unvested restricted stock units 367,101 9,699 Warrants to purchase common stock 6,544,070 3,579,284 Total 6,913,670 3,591,553

Stock-based Compensation (Table

Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Summary of RSU activity	Summary of RSU activity Number Weighted- Unvested units at December 31, 2020 9,699 $ 19.97 Granted 360,750 2.94 Vested (3,348 ) 22.67 Forfeited – – Unvested units at December 31, 2021 367,101 $ 3.21
Summary of Stock Option Activity	Summary of Stock Option Activity Total Number Weighted- Weighted- Aggregate Balance at December 31, 2020 2,570 $ 3,334.06 Granted – – Exercised – – Cancelled (71 ) 946.27 Balance at December 31, 2021 2,499 $ 3,401.90 5.39 $ – Exercisable at December 31, 2021 2,153 $ 3,932.78 5.20 $ –
Details of Stock-based Compensation Expense	Details of Stock-based Compensation Expense December 31, 2021 2020 Research and development $ 117 $ 22 General and administrative 363 114 Total stock-based compensation $ 480 $ 136

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Components of Federal and State Income Tax Expense	Components of Federal and State Income Tax Expense Years Ended December 31, 2021 2020 Current Federal $ – $ – State – – Total current – – Deferred Federal (3,016 ) 9,780 State (1,329 ) 5,548 Total deferred (4,345 ) 15,328 Valuation allowance 4,345 (15,328 ) Total provision for income taxes $ – $ –
Schedule of effective income tax reconciliation	Schedule of effective income tax reconciliation Years Ended December 31, 2021 2020 Federal statutory rate 21.0 21.0 State income taxes, net of federal benefit 8.5 6.7 Non-deductible expenses   0.2   (0.5 )  Income tax credits 4.3 2.1 Valuation allowance ( 34.0 ) ( 29.3 ) Effective tax rate 0.0 0.0
Schedule of deferred tax assets	Schedule of deferred tax assets Years Ending December 31, 2021 2020 Deferred tax assets: Net operating loss carryforwards $ 10,150 $ 6,355 Tax credit carryforwards 946 – Stock-based compensation 1,363 1,374 Licensing deduction deferral 2,018 2,376 Lease liability 79 111 Other timing differences 169 196 Deferred tax assets 14,725 10,412 Deferred tax liabilities: Right of use asset (76 ) (108 ) Deferred tax liability (76 ) (108 ) Valuation allowance (14,649 ) (10,304 ) Net deferred tax asset $ – $ –

Schedule of Cash (Details)

Schedule of Cash (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Cash	$ 24,057	$ 14,244
Restricted cash	50	50
Cash and restricted cash shown in the statement of cash flows	$ 24,107	$ 14,294	$ 6,984

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details - Property useful lives)	12 Months Ended
	Dec. 31, 2021
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	3 years
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	5 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	5 years

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
SignificantAccountingPoliciesLineItems [Line Items]
Cash FDIC Insured Amount	$ 250,000
Impairment of Long-Lived Assets	0	$ 0
Fair Value, Inputs, Level 2 [Member]
SignificantAccountingPoliciesLineItems [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	$ 50,000	50,000
Research And Development [Member]
SignificantAccountingPoliciesLineItems [Line Items]
Prior Period Reclassification Adjustment		$ 715,000

Property and Equipment (Details

Property and Equipment (Details - Schedule of Property and Equipment) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Computer equipment	$ 195	$ 108
Machinery & equipment	992	1,035
Furniture & fixtures	46	49
Leasehold improvements	46	46
Total gross fixed assets	1,279	1,238
Less: accumulated depreciation and amortization	(1,122)	(1,105)
Property and equipment, net	$ 157	$ 133	$ 157

Property and Equipment (Detai_2

Property and Equipment (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation and amortization expens	$ 75,000	$ 72,000

Accrued Expenses (Details - Sch

Accrued Expenses (Details - Schedule of Accrued Expenses) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Compensation and benefits	$ 572	$ 618
Professional fees	102	81
Research and development costs	1,986	549
Other		104
Total accrued expenses and other current liabilities	$ 2,660	$ 1,352

Leases (Details - Balance sheet

Leases (Details - Balance sheet lease items) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Right of use asset	$ 283	$ 400
Lease liability, current	125	116
Lease liability, non-current	170	295
Total lease liability	$ 295	$ 411
Weighted average remaining lease term	2 years 3 months	3 years 3 months
Operating Lease, Weighted Average Discount Rate, Percent	4.70%

Leases (Details - Future lease

Leases (Details - Future lease payments) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
2022	$ 135
2023	140
2024	35
Total lease payments	310
Less: Imputed interest	(15)
Total operating lease liabilities (includes current portion)	$ 295	$ 411

Leases (Details Narrative)

Leases (Details Narrative) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)ft²	Dec. 31, 2020USD ($)
Operating Lease, Cost	$ 132,000	$ 132,000
Operating lease payments	$ 131,600	$ 127,800
Property Subject to Operating Lease [Member]
Operating lease footage | ft²	7,581
Lease expiration date	Mar. 31, 2024

Debt (Details Narrative)

Debt (Details Narrative) - USD ($) $ in Thousands	4 Months Ended	12 Months Ended
	May 11, 2020	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Proceeds from debt		$ 0	$ 231
Gain on loan extinguishment		233	$ 0
PPP Loan [Member]
Debt Instrument [Line Items]
Proceeds from debt	$ 231,252
Debt maturity date	May 11, 2022
Debt interest rate	1.00%
Gain on loan extinguishment		$ 233

Commitments and Contingencies -

Commitments and Contingencies - (Details - Future Cash Payments) $ in Thousands	Dec. 31, 2021USD ($)
Commitments and Contingencies Disclosure [Abstract]
2022	$ 100
2023	100
2024	100
2025	100
2026	100
Thereafter	300
Total	$ 800

Stockholders' Equity (Details -

Stockholders' Equity (Details - Warrants outstanding) - Warrant [Member] - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Class of Warrant or Right [Line Items]
Warrants outstanding	6,544,070	3,579,284
Warrants issued	4,071,340
Warrants exercised	(1,083,321)
Warrants expired	(23,233)
Dec 2016 Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price	$ 495
Warrant expiration date	Dec. 21, 2021
Warrants outstanding	0	23,233
Warrants issued
Warrants exercised
Warrants expired	(23,233)
April 2018 Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price	$ 173.25
Warrant expiration date	May 31, 2023
Warrants outstanding	20,599	20,599
Warrants issued
Warrants exercised
Warrants expired
April 2018 Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price	$ 223
Warrant expiration date	Apr. 9, 2023
Warrants outstanding	1,373	1,373
Warrants issued
Warrants exercised
Warrants expired
October 2018 Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price	$ 10.45
Warrant expiration date	Oct. 3, 2025
Warrants outstanding	389,610	389,610
Warrants issued
Warrants exercised
Warrants expired
October 2018 Underwriter Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price	$ 13.06
Warrant expiration date	Oct. 1, 2023
Warrants outstanding	29,220	29,220
Warrants issued
Warrants exercised
Warrants expired
Nov 2019 Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price	$ 6.875
Warrant expiration date	Nov. 18, 2024
Warrants outstanding	13,636	13,636
Warrants issued
Warrants exercised
Warrants expired
Feb 2020 Registered Direct Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price	$ 8.71
Warrant expiration date	Aug. 6, 2025
Warrants outstanding	197,056	197,056
Warrants issued
Warrants exercised
Warrants expired
Feb 2020 Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price	$ 11.0375
Warrant expiration date	Feb. 4, 2025
Warrants outstanding	14,779	14,779
Warrants issued
Warrants exercised
Warrants expired
Feb 2020 Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price	$ 4
Warrant expiration date	Feb. 13, 2025
Warrants outstanding	1,326,500	1,326,500
Warrants issued
Warrants exercised
Warrants expired
Feb 2020 Underwriter Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price	$ 5
Warrant expiration date	Feb. 11, 2025
Warrants outstanding	150,000	150,000
Warrants issued
Warrants exercised
Warrants expired
April 2020 Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price	$ 2.21
Warrant expiration date	Oct. 2, 2025
Warrants outstanding	428,266	1,284,798
Warrants issued
Warrants exercised	(856,532)
Warrants expired
April 2020 Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price	$ 2.9188
Warrant expiration date	Mar. 31, 2025
Warrants outstanding	41,756	128,480
Warrants issued
Warrants exercised	(86,724)
Warrants expired
January 2021 Pre-Funded Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price	$ 0.001
Warrants outstanding	0
Warrants issued	140,065
Warrants exercised	(140,065)
Warrants expired
January 2021 Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price	$ 3
Warrant expiration date	Jul. 27, 2026
Warrants outstanding	3,420,696
Warrants issued	3,420,696
Warrants exercised
Warrants expired
January 2021 Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price	$ 3.8375
Warrant expiration date	Jul. 27, 2026
Warrants outstanding	342,070
Warrants issued	342,070
Warrants exercised
Warrants expired
February 2021 Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price	$ 4.275
Warrant expiration date	Feb. 12, 2026
Warrants outstanding	168,509
Warrants issued	168,509
Warrants exercised
Warrants expired

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)	1 Months Ended			2 Months Ended	3 Months Ended	12 Months Ended
	Jan. 25, 2021	Feb. 13, 2020	Feb. 06, 2020	Feb. 17, 2021	Apr. 02, 2020	Dec. 31, 2021	Dec. 31, 2020
Class of Stock [Line Items]
Proceeds from exercise of warrants						$ 2,146,000	$ 3,856,000
April 2020 Warrants [Member] | Warrant [Member]
Class of Stock [Line Items]
Conversion of stock, shares converted							428,266
Warrants [Member]
Class of Stock [Line Items]
Proceeds from exercise of warrants						$ 0
Common Stock [Member] | April 2020 Warrants [Member]
Class of Stock [Line Items]
Conversion of stock, shares issued							225,796
Jan 2021 Private Placement [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues	4,420,863
Shares Issued, Price Per Share	$ 3.07
Proceeds from issuance of stock and warrants	$ 12,669,000
Jan 2021 Private Placement [Member] | Jan 2021 Pre Funded Warrants [Member]
Class of Stock [Line Items]
Shares Issued, Price Per Share	$ 3.069
Warrants issued	140,065
Jan 2021 Private Placement [Member] | Jan 2021 Warrants [Member]
Class of Stock [Line Items]
Warrants issued	3,420,696
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 3
Jan 2021 Private Placement [Member] | Jan 2021 Placement Agent Warrants [Member]
Class of Stock [Line Items]
Warrants issued	342,070
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 3.8375
Feb 2021 Registered Direct Offering [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues				2,246,784
Shares Issued, Price Per Share				$ 3.42
Proceeds from issuance of stock and warrants				$ 6,908,000
Feb 2021 Registered Direct Offering [Member] | Feb 2021 Placement Agent Warrants [Member]
Class of Stock [Line Items]
Warrants issued				168,509
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 4.275
Feb 2020 Registered Offering [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues			197,056
Shares Issued, Price Per Share			$ 8.705
Proceeds from issuance of stock and warrants			$ 1,467,000
Feb 2020 Registered Direct Warrants [Member]
Class of Stock [Line Items]
Shares Issued, Price Per Share			$ 0.125
Warrants issued			197,056
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 8.71
Feb 2020 Placement Agent Warrants [Member]
Class of Stock [Line Items]
Warrants issued			14,779
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 11.0375
Feb 2020 Underwritten Public Offering [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues		993,633
Shares Issued, Price Per Share		$ 4
Proceeds from issuance of stock and warrants		$ 7,093,000
Feb 2020 Underwritten Public Offering [Member] | 2020 Pre-Funded Warrants [Member]
Class of Stock [Line Items]
Shares Issued, Price Per Share		$ 3.999
Warrants issued		1,006,367
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.001
Feb 2020 Underwritten Public Offering [Member] | February 2020 Warrants [Member]
Class of Stock [Line Items]
Warrants issued		2,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 4
Feb 2020 Underwritten Public Offering [Member] | February 2020 Underwriter Warrants [Member]
Class of Stock [Line Items]
Warrants issued		150,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 5
Feb 2020 Underwritten Public Offering [Member] | Feb 2020 Warrants [Member] | Underwriter [Member]
Class of Stock [Line Items]
Shares Issued, Price Per Share		$ 0.001
Warrants issued		300,000
Option to purchase shares of common stock, shares		300,000
Option to purchase shares of common stock, price per share		$ 3.999
April 2020 Offering [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues					1,713,064
Shares Issued, Price Per Share					$ 2.21
Proceeds from issuance of stock and warrants					$ 3,527,000
April 2020 Offering [Member] | April 2020 Warrants [Member]
Class of Stock [Line Items]
Shares Issued, Price Per Share					$ 0.125
Warrants issued					1,713,064
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 2.21
April 2020 Offering [Member] | April 2020 Placement Agent Warrants [Member]
Class of Stock [Line Items]
Warrants issued					128,480
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 2.9188

Net Loss per Share (Details - A

Net Loss per Share (Details - Antidilutive shares) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total amount of anti-dilutive securities excluded from computation of earnings per share	6,913,670	3,591,553
Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total amount of anti-dilutive securities excluded from computation of earnings per share	2,499	2,570
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total amount of anti-dilutive securities excluded from computation of earnings per share	367,101	9,699
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total amount of anti-dilutive securities excluded from computation of earnings per share	6,544,070	3,579,284

Stock-based Compensation (Detai

Stock-based Compensation (Details - RSU activity) - Restricted Stock Units (RSUs) [Member]	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSU's unvested units, beginning balance | shares	9,699
RSU beginning balance, price per share | $ / shares	$ 19.97
RSU's granted | shares	360,750
RSU's granted, price per share | $ / shares	$ 2.94
RSU's vested | shares	(3,348)
RSU's vested, price per share | $ / shares	$ 22.67
RSU's forfeited | shares	0
RSU's forfeited, price per share | $ / shares	$ 0
RSU's unvested units, ending balance | shares	367,101
RSU ending balance, price per share | $ / shares	$ 3.21

Stock-based Compensation (Det_2

Stock-based Compensation (Details - Option activity) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)$ / sharesshares
Equity Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding | shares	2,570
Weighted-Average Exercise Price Per Share, Beginning Balance | $ / shares	$ 3,334.06
Options granted | shares	0
Weighted-Average Exercise Price Per Share, Granted | $ / shares	$ 0
Options exercised | shares	0
Options cancelled | shares	(71)
Weighted-Average Exercise Price Per Share, Cancelled | $ / shares	$ 946.27
Options outstanding | shares	2,499
Weighted-Average Exercise Price Per Share, Ending Balance | $ / shares	$ 3,401.90
Weighted-Average Contractual Term, Outstanding	5 years 4 months 20 days
Aggregate Intrinsic Value, Ending Balance | $	$ 0
Options exercisable | shares	2,153
Weighted-Average Exercise Price Per Share, Exercisable | $ / shares	$ 3,932.78
Weighted-Average Contractual Term, Exercisable	5 years 2 months 12 days
Aggregate Intrinsic Value, Exercisable | $	$ 0
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-Average Exercise Price Per Share, Exercised | $ / shares	$ 0

Stock-based Compensation (Det_3

Stock-based Compensation (Details - Share-based compensation) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 480	$ 136
Research and Development Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	117	22
General and Administrative Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 363	$ 114

Stock-based Compensation (Det_4

Stock-based Compensation (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 480,000	$ 136,000
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	443,000	85,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value	9,400
Share-based compensation expense	$ 770,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition	2 years 10 days
Equity Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 37,000	$ 51,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition	6 months 29 days
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount	$ 21,000
Plan 2020 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	1,267,675
Plan 2020 [Member] | Outstanding Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	2,499
Plan 2020 [Member] | Unvested RSU's [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	367,101
Plan 2020 [Member] | Other shares available for future grant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	894,227

Income Taxes - (Details - Compo

Income Taxes - (Details - Components of Federal and State Income Tax Expense) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Current
Federal	$ 0	$ 0
State	0	0
Total current	0	0
Deferred
Federal	(3,016)	9,780
State	(1,329)	5,548
Total deferred	(4,345)	15,328
Valuation allowance	4,345	(15,328)
Total provision for income taxes	$ 0	$ 0

Income Taxes - (Details - Effec

Income Taxes - (Details - Effect Income Tax Rate Reconciliation)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Federal statutory rate	21.00%	21.00%
State income taxes, net of federal benefit	8.50%	6.70%
Non-deductible expenses	0.20%	(0.50%)
Income tax credits	4.30%	2.10%
Valuation allowance	34.00%	29.30%
Effective tax rate	0.00%	0.00%

Income Taxes - (Details - Com_2

Income Taxes - (Details - Components of Net Deferred Tax Assets) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets:
Net operating loss carryforwards	$ 10,150	$ 6,355
Tax credit carryforwards	946
Stock-based compensation	1,363	1,374
Licensing deduction deferral	2,018	2,376
Lease liability	79	111
Other timing differences	169	196
Deferred tax assets	14,725	10,412
Deferred tax liabilities:
Right of use asset	(76)	(108)
Deferred tax liability	(76)	(108)
Valuation allowance	(14,649)	(10,304)
Net deferred tax asset	$ 0	$ 0

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating Loss Carryforwards [Line Items]
Tax Credit Carryforward, Expiration Date	Dec. 31, 2042
Reduction in tax credit carryforward deferred tax asset		$ 2,017,000
Reduction in operating loss carryforward deferred tax asset		15,952,000
Reduction in valuation allowance, deferred tax asset		17,969,000
Federal [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 42,900,000
NOL carryforward indefinitely	42,579,000
NOL carryforward with expiration	$ 321,000
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2031
Research tax credits	$ 573,000
Reduction in operating loss carryforwards		55,000,000
Reduction in tax credit carryforward deferred tax asset		1,400,000
State [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 18,100,000
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2038
Research tax credits	$ 472,000
Reduction in operating loss carryforwards		70,000,000
Reduction in tax credit carryforward deferred tax asset		$ 700,000